Lenvabuzz 10mg Capsule is indicated to treat the following conditions:

• Certain types of advanced thyroid cancer
• Advanced Liver cancer
• Certain types of kidney cancer
• Endometrial cancer

Lenvabuzz 10mg Capsule blocks the enzyme receptor tyrosine kinases (RTKs). RTKs develop new blood vessels that supply oxygen and nutrients to the cells and help them grow. This medicine inhibits the receptors that facilitate the growth of blood vessels in tumor cells. RTKs are present in high concentrations in cancer cells, and administration of this medicine slows down the rate of cancer cells’ growth and multiplication.

Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Lenvabuzz 10mg Capsule and reduce effectiveness by causing undesirable side effects. 

• Lenvabuzz 10mg Capsule should be stored at room temperature, between 20°C to 25°C (68°F to 77°F).
• Protected from light.
• Keep it in its original packaging until it is ready to be used.
• Keep it out of the reach of children and pets.
• It should be disposed of properly.

Lenvabuzz 10mg Capsule is an oral medication that is usually taken once a day, at approximately the same time each day, with or without food. It should be taken as prescribed by a doctor or other healthcare provider. These capsules should be swallowed whole with a glass of water. They should not be crushed, chewed, or opened, as this can affect the way the medication is absorbed and decrease its effectiveness. You should not take a double dose to make up for the second dose.

Like all medications, Lenvabuzz 10mg Capsule Injection can cause side effects, although not everyone who takes it will experience them. 

Serious:

• Feeling numb or weak on 1 side of the body
• Severe headache
• Fever
• Confusion
• Difficulty speaking
• Vision changes
• Dizziness
• Chest pain or pressure
• Pain in arms, jaw, neck, back
• Breathing problems
• Severe stomach pain
• Blood clot formation
• Blood in stools or coughing blood
• Liver problems
• Pain or soreness in the mouth, teeth or jaw

Common:

• High or low BP
• Loss of appetite
• Nausea, vomiting, constipation, diarrhoea or indigestion
• Tiredness
• Hoarse voice
• Leg swelling
• Rashes
• Pain in joints or muscles
• Hair loss
• Sleeplessness
• Protein in urine, frequent urination
• Low potassium, magnesium and calcium levels in the blood
• Dehydration
• Skin problems
• Gall bladder inflammation
• Increase in the values of cholesterol, thyroid-stimulating hormone, digestive enzymes
• Delayed wound healing

If you are receiving close communication with your healthcare provider, report any concerns or side effects as soon as possible. Avoid getting pregnant and breastfeeding during treatment. Patients should use effective contraception while taking Lenvabuzz 10mg Capsule and for at least two weeks after stopping treatment. Patients should avoid eating grapefruits as they affect the absorption of this drug. Patients should use sunscreen and wear protective clothing while outdoors to reduce the risk of sunburn or skin damage. 

You should avoid strenuous activities or exercise until you know how this medication is affecting you. Maintain a healthy and balanced diet during treatment to support your overall health and well-being. By being informed and engaged in your treatment, you can help ensure the best possible outcomes and manage any associated potential risks or complications. 

1. Eisai Europe Limited, Electronic Medicines Compendium (EMC), [Revised on Mar 2021] [Accessed on 20th April 2023], https://www.medicines.org.uk/emc/files/pil.6840.pdf
2. Suyama and Iwase, Lenvatinib: A promising molecular targeted agent for multiple cancers, Cancer Control, 2018, 25, 1-5, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056795/pdf/10/1177 1073274818789361.pdf
3. Q.M. Anstee, D.E.J. Jones, Liver and Biliary Tract Disease, Davidson’s Principles and Practice of Medicine, 22nd Edition, 2014, 921-988.
4. M.W.J. Strachan, J. Newell-Price, Endocrine disease, Davidson’s Principles & Practice of Medicine, 22nd Edition, 2014, 733-796.
5. Eisai Inc U.S Food and Safety Drug Administration (FDA) [Last revised Aug 2018], [Accessed on 20th April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206947s007lbl.pdf